NASDAQ:KMPH - KemPharm Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.30 +0.20 (+3.28 %)
(As of 05/24/2018 02:25 AM ET)
Previous Close$6.30
Today's Range$6.20 - $6.80
52-Week Range$2.45 - $8.40
Volume195,264 shs
Average Volume95,592 shs
Market Capitalization$95.16 million
P/E Ratio-2.13
Dividend YieldN/A
Beta-0.28

About KemPharm (NASDAQ:KMPH)

KemPharm logoKemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of attention deficit hyperactivity disorder. It also provides APADAZ, an immediate-release (IR) combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. In addition, the company develops KP201/IR, an acetaminophen-free immediate-release formulation of APADAZ for treating short-term management of acute pain; and KP511/ER and KP511/IR hydromorphone product candidates for the treatment of pain. Further, it is developing KP606, a prodrug of oxycodone for the management of moderate to severe pain; KP746, a prodrug of oxymorphone for the management of moderate to severe pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders. The company was founded in 2006 and is headquartered in Coralville, Iowa.

Receive KMPH News and Ratings via Email

Sign-up to receive the latest news and ratings for KMPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KMPH
CUSIPN/A
Phone319-665-2575

Debt

Debt-to-Equity Ratio-1.13
Current Ratio2.83
Quick Ratio2.83

Price-To-Earnings

Trailing P/E Ratio-2.13
Forward P/E Ratio-1.91
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($5.28) per share
Price / Book-1.19

Profitability

EPS (Most Recent Fiscal Year)($2.96)
Net Income$-43,380,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-77.95%

Miscellaneous

Employees32
Outstanding Shares15,100,000

KemPharm (NASDAQ:KMPH) Frequently Asked Questions

What is KemPharm's stock symbol?

KemPharm trades on the NASDAQ under the ticker symbol "KMPH."

How were KemPharm's earnings last quarter?

KemPharm (NASDAQ:KMPH) released its quarterly earnings data on Thursday, May, 10th. The specialty pharmaceutical company reported ($1.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by $0.41. View KemPharm's Earnings History.

When is KemPharm's next earnings date?

KemPharm is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for KemPharm.

What price target have analysts set for KMPH?

5 Wall Street analysts have issued 1 year target prices for KemPharm's shares. Their forecasts range from $9.00 to $17.00. On average, they anticipate KemPharm's stock price to reach $12.00 in the next year. View Analyst Ratings for KemPharm.

What are Wall Street analysts saying about KemPharm stock?

Here are some recent quotes from research analysts about KemPharm stock:
  • 1. According to Zacks Investment Research, "KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. " (5/17/2018)
  • 2. Canaccord Genuity analysts commented, "We are encouraged by KemPharm’s progress with the ADHD program, and believe it represents a significant value-creating opportunity in the coming quarters. We maintain our BUY rating and $11 PT on KMPH shares. Positive IV Human Abuse Potential data bode well for upcoming ADHD reads. KemPharm announced positive results for their KP415 human abuse study, showing drug liking scores similar to placebo when administered up to the highest safest dose. There was no significant difference in mean and placebo. However, there was a numerically significant difference in mean and d-methylphenidate at equimolar doses. Drug liking is a proxy for the potential for drug abuse." (5/10/2018)

Who are some of KemPharm's key competitors?

Who are KemPharm's key executives?

KemPharm's management team includes the folowing people:
  • Dr. Travis C. Mickle, Co-Founder, Pres, Chief Exec. Officer & Chairman (Age 45)
  • Mr. Daniel L. Cohen, Exec. VP of Gov. & PR (Age 59)
  • Dr. Sven Guenther Ph.D., Exec. VP of R&D (Age 46)
  • Mrs. Christal M. M. Mickle M.A., Co-Founder & VP of Operations & Product Devel. (Age 39)
  • Mr. R. LaDuane Clifton CPA, CFO, Sec. & Treasurer (Age 46)

When did KemPharm IPO?

(KMPH) raised $60 million in an IPO on Thursday, April 16th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.

Has KemPharm been receiving favorable news coverage?

News coverage about KMPH stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. KemPharm earned a media sentiment score of 0.21 on Accern's scale. They also assigned media coverage about the specialty pharmaceutical company an impact score of 45.57 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are KemPharm's major shareholders?

KemPharm's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Arete Wealth Advisors LLC (3.72%), C WorldWide Group Holding A S (2.57%), Victory Capital Management Inc. (1.19%), ING Groep NV (0.92%), JPMorgan Chase & Co. (0.67%) and BlackRock Inc. (0.43%). Company insiders that own KemPharm stock include Daniel L Cohen, David S Tierney, Delaware Street Capital Master, Gordon K Johnson, R Laduane Clifton and Travis C Mickle. View Institutional Ownership Trends for KemPharm.

Which major investors are selling KemPharm stock?

KMPH stock was sold by a variety of institutional investors in the last quarter, including Arete Wealth Advisors LLC, C WorldWide Group Holding A S and BlackRock Inc.. View Insider Buying and Selling for KemPharm.

Which major investors are buying KemPharm stock?

KMPH stock was purchased by a variety of institutional investors in the last quarter, including ING Groep NV, JPMorgan Chase & Co., Change Path LLC, Royal Bank of Canada, Victory Capital Management Inc. and Millennium Management LLC. Company insiders that have bought KemPharm stock in the last two years include Daniel L Cohen, David S Tierney, Delaware Street Capital Master, Gordon K Johnson, R Laduane Clifton and Travis C Mickle. View Insider Buying and Selling for KemPharm.

How do I buy shares of KemPharm?

Shares of KMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is KemPharm's stock price today?

One share of KMPH stock can currently be purchased for approximately $6.30.

How big of a company is KemPharm?

KemPharm has a market capitalization of $95.16 million. The specialty pharmaceutical company earns $-43,380,000.00 in net income (profit) each year or ($2.96) on an earnings per share basis. KemPharm employs 32 workers across the globe.

How can I contact KemPharm?

KemPharm's mailing address is 2500 CROSSPARK ROAD SUITE E126, CORALVILLE IA, 52241. The specialty pharmaceutical company can be reached via phone at 319-665-2575 or via email at [email protected]


MarketBeat Community Rating for KemPharm (KMPH)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  215 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  335
MarketBeat's community ratings are surveys of what our community members think about KemPharm and other stocks. Vote "Outperform" if you believe KMPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KMPH will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

KemPharm (NASDAQ:KMPH) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for KemPharm in the last 12 months. Their average twelve-month price target is $12.00, suggesting that the stock has a possible upside of 90.48%. The high price target for KMPH is $17.00 and the low price target for KMPH is $9.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $12.00$10.75$10.25$9.00
Price Target Upside: 90.48% upside58.09% upside70.83% upside181.25% upside

KemPharm (NASDAQ:KMPH) Consensus Price Target History

Price Target History for KemPharm (NASDAQ:KMPH)

KemPharm (NASDAQ:KMPH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/23/2018Janney Montgomery ScottInitiated CoverageBuy ➝ Buy$17.00HighView Rating Details
5/10/2018OppenheimerSet Price TargetBuy$13.00HighView Rating Details
5/10/2018Canaccord GenuityReiterated RatingBuy$11.00HighView Rating Details
4/2/2018Roth CapitalSet Price TargetBuy$10.00MediumView Rating Details
1/16/2018Royal Bank of CanadaSet Price TargetBuy$9.00MediumView Rating Details
(Data available from 5/24/2016 forward)

Earnings

KemPharm (NASDAQ:KMPH) Earnings History and Estimates Chart

Earnings by Quarter for KemPharm (NASDAQ:KMPH)

KemPharm (NASDAQ:KMPH) Earnings Estimates

2018 EPS Consensus Estimate: ($2.61)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.72)($0.72)($0.72)
Q2 20181($0.72)($0.72)($0.72)
Q3 20181($0.60)($0.60)($0.60)
Q4 20181($0.57)($0.57)($0.57)

KemPharm (NASDAQ KMPH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2018($0.84)N/AView Earnings Details
5/10/2018Q1 2018($0.70)($1.11)ViewN/AView Earnings Details
3/29/2018Q4 2017($0.68)($0.72)ViewListenView Earnings Details
11/9/2017Q3 2017($0.69)($0.68)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.63)($0.44)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.63)($0.84)ViewN/AView Earnings Details
3/9/2017Q4 2016($0.70)($0.68)ViewListenView Earnings Details
11/9/2016Q3 2016($0.70)($0.92)ViewListenView Earnings Details
8/10/2016Q2($0.94)($0.58)ViewListenView Earnings Details
5/12/2016Q1($0.56)($0.20)ViewListenView Earnings Details
3/10/2016Q4($0.50)($0.64)ViewListenView Earnings Details
11/12/2015Q315($0.48)($0.68)ViewListenView Earnings Details
8/13/2015Q215($0.47)($0.59)ViewListenView Earnings Details
5/27/2015Q1($0.49)($2.50)ViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

KemPharm (NASDAQ:KMPH) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

KemPharm (NASDAQ KMPH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 25.90%
Institutional Ownership Percentage: 36.49%
Insider Trading History for KemPharm (NASDAQ:KMPH)
Institutional Ownership by Quarter for KemPharm (NASDAQ:KMPH)

KemPharm (NASDAQ KMPH) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/15/2018Daniel L CohenEVPBuy7,900$6.45$50,955.0035,500View SEC Filing  
11/27/2017Daniel L CohenEVPBuy7,500$3.79$28,425.00View SEC Filing  
9/25/2017R. Laduane CliftonCFOBuy300$3.78$1,134.001,575View SEC Filing  
9/14/2017Delaware Street Capital MasterMajor ShareholderBuy325,888$3.27$1,065,653.76View SEC Filing  
8/24/2017Daniel L CohenEVPBuy5,000$2.58$12,900.0025,000View SEC Filing  
8/24/2017Gordon K JohnsonInsiderBuy4,000$2.60$10,400.003,000View SEC Filing  
6/20/2017Travis C MickleCEOBuy8,000$3.45$27,600.001,629,612View SEC Filing  
6/19/2017R. Laduane CliftonCFOBuy275$3.30$907.501,275View SEC Filing  
5/25/2017Daniel L CohenEVPBuy2,500$4.11$10,275.0019,474View SEC Filing  
3/31/2017Daniel L CohenEVPBuy2,500$4.48$11,200.0016,500View SEC Filing  
3/24/2017R. Laduane CliftonCFOBuy1,000$4.24$4,240.00900View SEC Filing  
3/22/2017Travis C MickleCEOBuy2,000$4.10$8,200.001,526,081View SEC Filing  
3/20/2017David S TierneyDirectorBuy1,000$4.20$4,200.006,000View SEC Filing  
11/30/2016Daniel L CohenEVPBuy5,000$3.50$17,500.0010,747View SEC Filing  
9/6/2016Daniel L CohenEVPBuy10,000$4.75$47,500.001,310View SEC Filing  
8/17/2016Travis C MickleCEOBuy5,000$4.95$24,750.001,381,176View SEC Filing  
3/29/2016Travis C MickleCEOBuy2,450$14.57$35,696.501,381,176View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

KemPharm (NASDAQ KMPH) News Headlines

Source:
DateHeadline
KemPharm (KMPH) Receives Consensus Recommendation of "Buy" from AnalystsKemPharm (KMPH) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 24 at 1:34 AM
Benzingas Top Upgrades, Downgrades For May 23, 2018Benzinga's Top Upgrades, Downgrades For May 23, 2018
www.benzinga.com - May 23 at 5:35 PM
US STOCKS ON THE MOVE-Ralph Lauren, bank stocks, Red Robin Gourmet, NordstromUS STOCKS ON THE MOVE-Ralph Lauren, bank stocks, Red Robin Gourmet, Nordstrom
www.nasdaq.com - May 23 at 5:35 PM
Janney Buys Into KemPharm Ahead Of Transformative Summer CatalystJanney Buys Into KemPharm Ahead Of 'Transformative' Summer Catalyst
finance.yahoo.com - May 23 at 5:35 PM
Janney Montgomery Scott Initiates Coverage on KemPharm (KMPH)Janney Montgomery Scott Initiates Coverage on KemPharm (KMPH)
www.americanbankingnews.com - May 23 at 12:45 PM
Who Are The Major Shareholders In KemPharm Inc (NASDAQ:KMPH)?Who Are The Major Shareholders In KemPharm Inc (NASDAQ:KMPH)?
finance.yahoo.com - May 18 at 5:59 PM
Daniel L. Cohen Acquires 7,900 Shares of KemPharm (KMPH) StockDaniel L. Cohen Acquires 7,900 Shares of KemPharm (KMPH) Stock
www.americanbankingnews.com - May 17 at 10:44 PM
KemPharm (KMPH) Cut to Sell at Zacks Investment ResearchKemPharm (KMPH) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - May 17 at 5:47 PM
KemPharm (KMPH) Upgraded to Buy at ValuEngineKemPharm (KMPH) Upgraded to Buy at ValuEngine
www.americanbankingnews.com - May 17 at 4:41 PM
KemPharm: Patients Not Liking Their Drugs Is Great NewsKemPharm: Patients Not Liking Their Drugs Is Great News
seekingalpha.com - May 14 at 8:28 AM
Zacks: Analysts Anticipate KemPharm (KMPH) Will Announce Earnings of -$0.67 Per ShareZacks: Analysts Anticipate KemPharm (KMPH) Will Announce Earnings of -$0.67 Per Share
www.americanbankingnews.com - May 14 at 3:27 AM
KemPharms (KMPH) CEO Travis Mickle on Q1 2018 Results - Earnings Call TranscriptKemPharm's (KMPH) CEO Travis Mickle on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 8:25 AM
KemPharma: 1Q Earnings SnapshotKemPharma: 1Q Earnings Snapshot
www.foxnews.com - May 12 at 8:25 AM
KemPharm Stock Breaks Out on Clinical Trial ResultsKemPharm Stock Breaks Out on Clinical Trial Results
finance.yahoo.com - May 11 at 5:58 PM
KemPharm (KMPH) Given a $13.00 Price Target by Oppenheimer AnalystsKemPharm (KMPH) Given a $13.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - May 11 at 3:57 PM
BLFS Q1 Revenue Up 61%, VRAY Garners Attention, AKCA Gets FDA Panel NodBLFS Q1 Revenue Up 61%, VRAY Garners Attention, AKCA Gets FDA Panel Nod
www.nasdaq.com - May 11 at 8:28 AM
Will KemPharm Inc’s (NASDAQ:KMPH) Earnings Grow Over The Next Few Years?Will KemPharm Inc’s (NASDAQ:KMPH) Earnings Grow Over The Next Few Years?
finance.yahoo.com - May 11 at 8:28 AM
KemPharm (KMPH) Receives "Buy" Rating from Canaccord GenuityKemPharm (KMPH) Receives "Buy" Rating from Canaccord Genuity
www.americanbankingnews.com - May 10 at 9:37 PM
BRIEF-KemPharm Reports Q1 Loss Per Share $1.77BRIEF-KemPharm Reports Q1 Loss Per Share $1.77
www.reuters.com - May 10 at 5:56 PM
KemPharm Announces Positive, Topline Results from an Intravenous Human Abuse Potential Trial with KP415 Prodrug ...KemPharm Announces Positive, Topline Results from an Intravenous Human Abuse Potential Trial with KP415 Prodrug ...
globenewswire.com - May 10 at 5:56 PM
KemPharm Announces Positive, Topline Results from an Intravenous Human Abuse Potential Trial with KP415 Prodrug; Reports Q1 2018 ResultsKemPharm Announces Positive, Topline Results from an Intravenous Human Abuse Potential Trial with KP415 Prodrug; Reports Q1 2018 Results
finance.yahoo.com - May 10 at 5:56 PM
KemPharm (KMPH) Cut to "Sell" at ValuEngineKemPharm (KMPH) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - May 8 at 3:29 PM
KemPharm (KMPH) Rating Increased to Hold at ValuEngineKemPharm (KMPH) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - May 2 at 11:33 PM
KemPharm, Inc. to Report First Quarter 2018 ResultsKemPharm, Inc. to Report First Quarter 2018 Results
finance.yahoo.com - May 1 at 8:26 AM
-$0.70 Earnings Per Share Expected for KemPharm (KMPH) This Quarter-$0.70 Earnings Per Share Expected for KemPharm (KMPH) This Quarter
www.americanbankingnews.com - April 26 at 3:10 PM
Blog Exposure - VBI Vaccines Announced Dosing of Last Patient in PROTECT Phase-3 Clinical Study for Sci-B-Vac® Hepatitis B VaccineBlog Exposure - VBI Vaccines Announced Dosing of Last Patient in PROTECT Phase-3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine
finance.yahoo.com - April 23 at 8:15 AM
KemPharm (KMPH) Lifted to Hold at Zacks Investment ResearchKemPharm (KMPH) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - April 18 at 10:16 PM
KemPharm (KMPH) Stock Rating Lowered by ValuEngineKemPharm (KMPH) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 18 at 1:24 PM
 Analysts Anticipate KemPharm (KMPH) Will Post Earnings of -$0.70 Per Share Analysts Anticipate KemPharm (KMPH) Will Post Earnings of -$0.70 Per Share
www.americanbankingnews.com - April 9 at 5:24 PM
KemPharm (KMPH) Upgraded to Sell by ValuEngineKemPharm (KMPH) Upgraded to Sell by ValuEngine
www.americanbankingnews.com - April 6 at 11:39 AM
KemPharm (KMPH) Upgraded at ValuEngineKemPharm (KMPH) Upgraded at ValuEngine
www.americanbankingnews.com - April 6 at 11:38 AM
KemPharm (KMPH) Downgraded by Zacks Investment ResearchKemPharm (KMPH) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 6 at 10:03 AM
KemPharm (KMPH) Raised to Buy at Zacks Investment ResearchKemPharm (KMPH) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - April 5 at 1:43 PM
Kempharm Removes The Albatross From Its Neck: Where Is The Company Now Sailing? (Update On Apadaz)Kempharm Removes The Albatross From Its Neck: Where Is The Company Now Sailing? (Update On Apadaz)
seekingalpha.com - April 5 at 10:11 AM
Oppenheimer Analysts Reduce Earnings Estimates for KemPharm (KMPH)Oppenheimer Analysts Reduce Earnings Estimates for KemPharm (KMPH)
www.americanbankingnews.com - April 5 at 7:38 AM
KemPharm (KMPH) Given Consensus Rating of "Buy" by BrokeragesKemPharm (KMPH) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 4 at 1:39 AM
KemPharm (KMPH) Given a $10.00 Price Target at Roth CapitalKemPharm (KMPH) Given a $10.00 Price Target at Roth Capital
www.americanbankingnews.com - April 3 at 11:11 AM
Oppenheimer Analysts Give KemPharm (KMPH) a $13.00 Price TargetOppenheimer Analysts Give KemPharm (KMPH) a $13.00 Price Target
www.americanbankingnews.com - April 2 at 12:26 PM
Kempharm (KMPH): Attention Shifting to KP415 Mid-Year Update - RBCKempharm (KMPH): Attention Shifting to KP415 Mid-Year Update - RBC
www.streetinsider.com - April 2 at 8:40 AM
KemPharm Inc (KMPH) Short Interest UpdateKemPharm Inc (KMPH) Short Interest Update
www.americanbankingnews.com - March 31 at 1:45 AM
KemPharm (KMPH) Rating Increased to Buy at Zacks Investment ResearchKemPharm (KMPH) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 30 at 8:24 PM
KemPharm (KMPH) Issues  Earnings ResultsKemPharm (KMPH) Issues Earnings Results
www.americanbankingnews.com - March 30 at 8:30 AM
KemPharms (KMPH) CEO Travis Mickle on Q4 2017 Results - Earnings Call TranscriptKemPharm's (KMPH) CEO Travis Mickle on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - March 30 at 8:23 AM
Breakeven On The Horizon For KemPharm Inc (NASDAQ:KMPH)Breakeven On The Horizon For KemPharm Inc (NASDAQ:KMPH)
finance.yahoo.com - March 30 at 8:23 AM
KemPharm (KMPH) Rating Lowered to Hold at Zacks Investment ResearchKemPharm (KMPH) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 29 at 7:28 PM
KemPharm (KMPH) Stock Rating Upgraded by Zacks Investment ResearchKemPharm (KMPH) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 29 at 11:43 AM
KemPharm (KMPH) Shares March Higher, Can It Continue? March 23, 2018KemPharm (KMPH) Shares March Higher, Can It Continue? March 23, 2018
www.zacks.com - March 25 at 8:27 AM
KemPharm (KMPH) Stock Rating Lowered by Zacks Investment ResearchKemPharm (KMPH) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 23 at 10:46 PM
 Brokerages Expect KemPharm Inc (KMPH) Will Announce Earnings of -$0.71 Per Share Brokerages Expect KemPharm Inc (KMPH) Will Announce Earnings of -$0.71 Per Share
www.americanbankingnews.com - March 23 at 5:16 PM
KemPharm (KMPH) Stock Rating Reaffirmed by OppenheimerKemPharm (KMPH) Stock Rating Reaffirmed by Oppenheimer
www.americanbankingnews.com - March 22 at 4:09 PM

SEC Filings

KemPharm (NASDAQ:KMPH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

KemPharm (NASDAQ:KMPH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

KemPharm (NASDAQ KMPH) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.